CJC-1295

Fat LossLong-acting GHRH analogExperimental

GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues).

Calculate Dose

For research use only.

Key Facts

CAS: 863288-34-0
Molecular Weight (MW): 3367.8 g/mol
Half-life: ~8 hours
Unit: mg
Administration Route: Subcutaneous
Frequency: 1× daily
Last updated: 8/23/2026
Targets: GHRH receptor

Overview

GHRH analog. Catalog “CJC-1295” often means the DAC (Drug Affinity Complex) form that extends half-life via albumin binding. Not FDA-approved. WADA S2 (GHRH analogues).

Protocol

Dosage Range: 1–2 mg per injection
Frequency: 1× daily
Cycle: 8–12 weeks on / 4 weeks off
Administration Route: Subcutaneous
Reconstitution Guide: Add 2 mL bacteriostatic water per 2 mg vial.

Science

Mechanism of Action

Binds GHRH receptors on pituitary somatotrophs to increase GH (and downstream IGF-1). The DAC maleimidopropionyl group covalently binds albumin, prolonging half-life versus native GRF(1–29).